SCHEMBL3015037

SCHEMBL3015037

COC(=O)C(Cc1ccccc1)NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 10/20 0.71
ADAMTS5 Q9UNA0 1/20 0.71
POLB P06746 2/20 0.62
MMP9 P14780 7/20 0.60
ADAMTS4 O75173 1/20 0.60
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
CA12 O43570 2/20 0.57
CA7 P43166 2/20 0.57
CA9 Q16790 2/20 0.57
CA14 Q9ULX7 2/20 0.57
ALDH1A1 P00352 1/20 0.57
MAPT P10636 1/20 0.57
CA2 P00918 1/20 0.57
CTSL P07711 2/20 0.57
CTSS P25774 1/20 0.57
NOS2 P35228 1/20 0.56
MMP1 P03956 1/20 0.54
MMP3 P08254 1/20 0.54
MMP7 P09237 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015042 1.00 MMP2 (0.71) MMP2ADAMTS5POLBMMP9ADAMTS4
SCHEMBL27568136 0.91 POLB (0.70) MMP2ADAMTS5POLBMMP9ADAMTS4
SCHEMBL15943338 0.90 MMP2 (0.75) MMP2ADAMTS5POLBMMP9ADAMTS4
SCHEMBL14534184 0.88 CTSL (0.67) MMP2ADAMTS5POLBMMP9ADAMTS4
SCHEMBL20335146 0.88 CTSL (0.67) MMP2ADAMTS5POLBMMP9ADAMTS4
SCHEMBL20335144 0.88 CTSL (0.67) MMP2ADAMTS5POLBMMP9ADAMTS4
SCHEMBL6323453 0.87 MMP2 (0.73) MMP2POLBMMP9ADAMTS4MEN1
SCHEMBL29540673 0.87 MMP2 (0.73) MMP2POLBMMP9ADAMTS4MEN1
SCHEMBL6323452 0.87 MMP2 (0.73) MMP2POLBMMP9ADAMTS4MEN1
SCHEMBL14191419 0.87 POLB (0.62) MMP2ADAMTS5POLBMMP9ADAMTS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100197749-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB 2010-08-05 US disclosed
US-20100197749-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB 2010-08-05 US disclosed
US-20100197749-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB 2010-08-05 US disclosed
US-7345095-B2 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC (US) 2008-03-18 US disclosed
US-20070129349-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER INC 2007-06-07 US disclosed
EP-1747195-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Incorporated (US) 2007-01-31 EP disclosed
US-7163942-B2 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2007-01-16 US disclosed
WO-2005095334-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2005-10-13 WO disclosed
US-20050222254-A1 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129349-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PSEN1, APP, PSEN2 MMP2 3165/4885ADAMTS5 3348/4885POLB 3643/4885
US-20100197749-A1 CHEMICAL COMPOUNDS EDF1, ECE1, EDNRA MMP2 2309/4885ADAMTS5 582/4885POLB 2808/4885
US-20050222254-A1 Sulfonamide compounds for the treatment of neurodegenerative disorders PSEN1, APP, PSEN2 MMP2 3078/4885ADAMTS5 3351/4885POLB 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.